Life sciences companies are struggling to raise money in the current financing environment – and this was the topic of a recent seminar in which I participated. Since PIPEs were the life blood of smaller, publicly-traded biotech companies during the last few years, there was general concern about how smaller life sciences companies can raise money today. Biotech companies used to be able to raise money by showing increased efficacy over the current standard of care even at a substantially higher cost. Jeremy Glaser is a corporate partner with Mintz Levin, a 500-person law firm that specializes in working with life sciences and technology companies. Communications through this Blog, whether posted or made through a private email to me, will not create an attorney-client relationship and, therefore, do not post on the Blog, or send me or anyone else through this Blog, secret or confidential information because such communications will not be entitled to protection by the attorney-client privilege. Finally, given the nature of a Blog, involving commentary and spontaneous thought that could change after reflection or further developments, I make no warranty or guarantee as to the accuracy, completeness or adequacy of information posted by anyone on this Blog, including me. read more

Technorati Tags: companies, blog, money, life, raise, deal, investor seminar news